JPRN-UMIN000000531已完成未知
Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20 - Phase II Study of Rituximab in MM w/CD20+
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who meet any one of the following criteria should be excluded from this study: 1)pregnant or lactating woman 2)patients with a history of receiving a murine, chimeric, humanized and/or human MoAb. 3) patients showing the following clinical laboratory values: peutrophil<1x109/L serum creatinine>Nu x2[Nu:institution normal upper value] ALT,AST,ALP>Nu x3 peripheral blood tumor cell>2x109/L 4) patients who is addicted to alcohol and/or drug, and/or patients with mental disease. 5)patients who have no other active malignancies, myelodysplastic syndrome, myelofibrosis, serious illness, complication or infection.
研究者
相似试验
已完成
不适用
Phase II study of rituximab in patients with severe systemic lupus erythematosusSystemic lupus erythematosusJPRN-UMIN000000763Zenyaku Kogyo Co., Ltd.30
已完成
2 期
Phase II study of rituximab containing induction chemotherapy (R-high-CHOP followed by CHASER) and high-dose chemotherapy (LEED) supported with auto-PBSCT for previously untreated patients with advanced mantle cell lymphoma(JCOG0406)newly diagnosed advanced mantle cell lymphomaJPRN-UMIN000001220Japan Clinical Oncology Group(JCOG)45
招募中
不适用
rituximab plus MG4101 in patients with relapsed or refractory indolent CD20-positive non-Hodgkin lymphomaNeoplasmsKCT0003250Seoul National University Hospital28
尚未招募
不适用
A study comparing Rituximab/Bendamustin (RB) alternating with Rituximab/Bendamustin/Cytarabin (RBAC) with Rituximab/Bendamustin (RB) therapy in elderly patients with mentle cell lymphomaKCT0007009Samsung Medical Center90
已完成
2 期
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40